Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Enrolling by invitationOBSERVATIONAL
Enrollment

750

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2031

Conditions
Growth Hormone Deficiency in ChildrenBorn Small for Gestational Age
Interventions
DRUG

Norditropin® FlexPro®

Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.

Trial Locations (1)

89075

Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ), Ulm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY